Next Article in Journal
Nanostructured Surfaces of Dental Implants
Previous Article in Journal
Sericin Enhances the Bioperformance of Collagen-Based Matrices Preseeded with Human-Adipose Derived Stem Cells (hADSCs)
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2013, 14(1), 1890-1917; doi:10.3390/ijms14011890

Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising Directions

Department of Neurosurgery, One Medical Center Drive, West Virginia University School of Medicine, P.O. Box 9183, Morgantown, WV 26506, USA
The Center for Neuroscience, West Virginia University School of Medicine, Morgantown, WV 26506, USA
Department of Health Restoration, West Virginia University School of Nursing, Morgantown, WV 26506, USA
Department of Basic Pharmaceutical Sciences, West Virginia University School of Pharmacy, Morgantown, WV 26506, USA
Author to whom correspondence should be addressed.
Received: 9 November 2012 / Revised: 4 January 2013 / Accepted: 10 January 2013 / Published: 17 January 2013
View Full-Text   |   Download PDF [408 KB, uploaded 19 June 2014]   |  


The translation of neuroprotective agents for ischemic stroke from bench-to-bedside has largely failed to produce improved treatments since the development of tissue plasminogen activator (tPA). One possible reason for lack of translation is the failure to acknowledge the greatest risk factor for stroke, age, and other common comorbidities such as hypertension, obesity, and diabetes that are associated with stroke. In this review, we highlight both mechanisms of studying these factors and results of those that have been addressed. We also discuss the potential role of other lifestyle factors associated with an increased stroke risk such as sleep fragmentation and/or deprivation. Furthermore, many proposed therapeutic agents have targeted molecular mechanisms occurring soon after the onset of ischemia despite data indicating delayed patient presentation following ischemic stroke. Modulating inflammation has been identified as a promising therapeutic avenue consistent with preliminary success of ongoing clinical trials for anti-inflammatory compounds such as minocycline. We review the role of inflammation in stroke and in particular, the role of inflammatory cell recruitment and macrophage phenotype in the inflammatory process. Emerging evidence indicates an increasing role of neuro-immune crosstalk, which has led to increased interest in identification of peripheral biomarkers indicative of neural injury. It is our hope that identification and investigation of factors influencing stroke pathophysiology may lead to improved therapeutics.
Keywords: ischemic stroke; comorbidity; aging; macrophage polarization ischemic stroke; comorbidity; aging; macrophage polarization
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Turner, R.C.; Lucke-Wold, B.; Lucke-Wold, N.; Elliott, A.S.; Logsdon, A.F.; Rosen, C.L.; Huber, J.D. Neuroprotection for Ischemic Stroke: Moving Past Shortcomings and Identifying Promising Directions. Int. J. Mol. Sci. 2013, 14, 1890-1917.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top